aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Recommendation of “Hold” by Analysts

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have been assigned an average recommendation of “Hold” from the seven brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $25.6667.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of aTyr Pharma in a report on Monday, December 29th.

Institutional Trading of aTyr Pharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ATYR. Vanguard Group Inc. increased its position in aTyr Pharma by 21.0% during the third quarter. Vanguard Group Inc. now owns 5,630,935 shares of the company’s stock worth $4,060,000 after purchasing an additional 975,887 shares during the last quarter. UBS Group AG boosted its holdings in shares of aTyr Pharma by 158.1% in the 3rd quarter. UBS Group AG now owns 4,505,955 shares of the company’s stock valued at $3,249,000 after purchasing an additional 2,760,238 shares during the last quarter. Octagon Capital Advisors LP grew its stake in shares of aTyr Pharma by 7.5% during the 2nd quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company’s stock valued at $19,367,000 after buying an additional 268,000 shares during the period. GSA Capital Partners LLP grew its stake in shares of aTyr Pharma by 272.2% during the 4th quarter. GSA Capital Partners LLP now owns 2,630,638 shares of the company’s stock valued at $2,060,000 after buying an additional 1,923,907 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of aTyr Pharma by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 2,283,717 shares of the company’s stock worth $1,789,000 after buying an additional 105,514 shares during the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

aTyr Pharma Price Performance

NASDAQ:ATYR opened at $0.96 on Friday. The firm has a market cap of $94.05 million, a PE ratio of -1.16 and a beta of 0.59. The firm has a 50 day simple moving average of $0.82 and a 200-day simple moving average of $1.58. aTyr Pharma has a 1-year low of $0.64 and a 1-year high of $7.29.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.